Compare DAIO & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | BTMD |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 31.0M |
| IPO Year | 2026 | 2021 |
| Metric | DAIO | BTMD |
|---|---|---|
| Price | $2.62 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.22 |
| AVG Volume (30 Days) | 28.4K | ★ 82.5K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ N/A |
| Revenue | $21,500,000.00 | ★ $192,219,000.00 |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $25.00 | $2.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.16 | $0.83 |
| 52 Week High | $4.49 | $2.90 |
| Indicator | DAIO | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 32.65 |
| Support Level | $2.28 | N/A |
| Resistance Level | $2.73 | $1.24 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 58.33 | 5.86 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.